Issued Patents All Time
Showing 1–25 of 32 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12383533 | Antimitotic amides for the treatment of cancer and proliferative disorders | — | 2025-08-12 |
| 12338261 | Alvocidib prodrugs having increased bioavailability | David J. Bearss | 2025-06-24 |
| 12077554 | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | Paul Flynn, Yuji Fujiwara, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi +2 more | 2024-09-03 |
| 11746103 | ALK-5 inhibitors and uses thereof | Bettina Franz, Steven L. Warner, Siva Reddy Basireddy, Srinivas Padakanti, Naresh Kumar | 2023-09-05 |
| 11529350 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | Jeyaprakashnarayanan Seenisamy, Steven L. Warner, Clifford J. Whatcott, David J. Bearss | 2022-12-20 |
| 11530231 | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | Paul Flynn, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka +1 more | 2022-12-20 |
| 11497756 | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib | David J. Bearss, Clifford J. Whatcott, Steven L. Warner | 2022-11-15 |
| 11471456 | Formulations comprising heterocyclic protein kinase inhibitors | Steven L. Warner, Paul Flynn | 2022-10-18 |
| 11400091 | AXL kinase inhibitors and use of the same | Steven L. Warner, Paul Flynn, David J. Bearss, Jason Marc Foulks, Nozomi Tomimatsu +4 more | 2022-08-02 |
| 11279694 | Alvocidib prodrugs and their use as protein kinase inhibitors | Yusuke Sawayama, Wataru Hirose, Hitoshi Ban | 2022-03-22 |
| 11129813 | Antimitotic amides for the treatment of cancer and proliferative disorders | — | 2021-09-28 |
| 11040038 | Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same | Steven L. Warner, David J. Bearss, Clifford J. Whatcott, Jason Marc Foulks, Stephen Patrick Anthony +3 more | 2021-06-22 |
| 11034710 | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | Paul Flynn, Yuji Fujiwara, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi +2 more | 2021-06-15 |
| 11013741 | AXL kinase inhibitors and use of the same | Paul Flynn, Akihito Nonoyama, Akihito Kiguchiya | 2021-05-25 |
| 10835537 | Combination therapies for treatment of cancer | David J. Bearss, Steven L. Warner, Clifford J. Whatcott, Wontak Kim | 2020-11-17 |
| 10772872 | Antimitotic amides for the treatment of cancer and proliferative disorders | — | 2020-09-15 |
| 10682356 | Combination therapies for treatment of cancer | David J. Bearss, Steven L. Warner, Clifford J. Whatcott, Wontak Kim | 2020-06-16 |
| 10568887 | Combination therapies for treatment of cancer | David J. Bearss, Steven L. Warner, Clifford J. Whatcott, Wontak Kim | 2020-02-25 |
| 10562925 | Alvocidib prodrugs having increased bioavailability | David J. Bearss | 2020-02-18 |
| 10422788 | Profiling peptides and methods for sensitivity profiling | David J. Bearss, Clifford J. Whatcott, Peter W. Peterson, Steven L. Warner, Lars Mouritsen | 2019-09-24 |
| 10267787 | Profiling peptides and methods for sensitivity profiling | David J. Bearss, Clifford J. Whatcott, Peter W. Peterson, Steven L. Warner, Lars Mouritsen | 2019-04-23 |
| 10259835 | Alvocidib prodrugs having increased bioavailability | David J. Bearss | 2019-04-16 |
| 10132797 | Profiling peptides and methods for sensitivity profiling | David J. Bearss, Clifford J. Whatcott, Peter W. Peterson, Steven L. Warner, Lars Mouritsen | 2018-11-20 |
| 10016398 | Antimitotic amides for the treatment of cancer and proliferative disorders | — | 2018-07-10 |
| 9758539 | Alvocidib prodrugs having increased bioavailability | David J. Bearss | 2017-09-12 |